Anti-oncomir suppression of tumor phenotypes

Molecular Interventions

Volumn 7, Issue 4, 2007, Pages 199-202

  Goga, Andrei ^a   Benz, Christopher ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIONCOMIR; MICRORNA; MICRORNA LET 7A; MICRORNA MIR 15; UNCLASSIFIED DRUG;

CANCER; CANCER INHIBITION; CANCER MODEL; CARCINOGENESIS; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; ONCOGENE MYC; ONCOGENE RAS; PHENOTYPE; PROTO ONCOGENE; REVIEW; T LYMPHOCYTE RECEPTOR GENE;

ANIMALS; HUMANS; MICRORNAS; NEOPLASMS; ONCOGENES; PHENOTYPE; SIGNAL TRANSDUCTION;

EID: 34548803681     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.7.4.6     Document Type: Review

References (23)

1. Calin, G.A., Ferracin, M., Cimmino, A. et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 353, 1793-1801 (2005). The first description of miRNA signatures as progostic markers in CLL.
2. Lu, J., Getz, G., Miska, E.A. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005). The first demonstration that miRNA profiling, rather than mRNA profiling, is better at defining the tissue origin of poorly differentiated cancers.
3. Mattie, M.D., Benz, C.C., Bowers, J. et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol. Cancer 5, 24 (2006).
4. Volinia, S., Calin, G.A., Liu, C.G. et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U.S.A. 103, 2257-2261 (2006).
5. Bagga, S., Bracht, J., Hunter, S., Massirer, K., Holtz, J., Eachus, R., and Pasquinelli, A.E. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 122, 553-563 (2005). Dispelled the widely held belief that miRNAs function solely by decreasing translation.
6. Lim, L.P., Glasner, M.E., Yekta, S., Burge, C.B., and Bartel, D.P. Vertebrate microRNA genes. Science 299, 1540 (2003).
7. Lewis, B.P., Shih, I.H., Jones-Rhoades, M.W., Bartel, D.P., and Burge, C.B. Prediction of mammalian microRNA targets. Cell 115, 787-98 (2003).
8. He, L., et al., A microRNA polycistron as a potential human oncogene. Nature 435, 828-833 (2005). Description of the first "oncomir" cluster and demonstration of cooperation with MYC for tumor formation.
9. Iorio, M.V., Ferracin, M., Liu, C.G. et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65, 7065-7070 (2005).
10. Johnson, S.M., Grosshans, H., Shingara, J. et al. RAS is regulated by the let-7 microRNA family. Cell 120, 635-647 (2005). Landmark paper demonstrating conservation of gene-miRNA pairing between C. elegans and humans.
11. O'Donnell, K.A., Wentzel, E.A., Zeller, K.I., Dang, C.V., and Mendell, J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435, 839-843 (2005). Copublished with (8), the authors showed that MYC can induce miRNA 17-92b cluster expression.
12. Voorhoeve, P.M., le Sage, C., Schrier, M. et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 124, 1169-1181 (2006). Largest published screen, to date, of miRNAs that functionally cooperate for tumor formation.
13. Kumar, M.S., Lu, J., Mercer, K.L., Golub, T.R., and Jacks, T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet. 39, 673-677 (2007). The authors were the first to demonstrate that loss of Dicer expression cooperates for tumor formation in a transgenic animal lung cancer model.
14. Wang, Y., Medvid, R., Melton, C., Jaenisch, R., and Blelloch, R. DGCR8 is essential for microRNA biogenesis and silencing of embryonic stem cell self-renewal. Nat. Genet. 39, 380-385 (2007).
15. Dews, M., Homayouni, A., Yu, D. et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat. Genet. 38, 1060-1065 (2006).
16. Cimmino, A., Calin, G.A., Fabbri, M. et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. U.S.A. 102, 13944-13949 (2005).
17. Scott, G.K., Goga, A., Bhaumik, D., Berger, C.E., Sullivan, C.S., and Benz, C.C. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J. Biol. Chem. 282, 1479-1486 (2007). First article to show that two genes in the same signaling pathway can be regulated by the same miRNA.
18. Pekarsky, Y., Santanam, U., Cimmino, A. et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 66, 11590-11593 (2006).
19. Virgilio, L., Narducci, M.G., Isobe, M., Billips, L.G., Cooper, M.D., Croce, C.M., and Russo, G. Identification of the TCL1 gene involved in T-cell malignancies. Proc. Natl. Acad. Sci. U.S.A. 91, 12530-12534 (1994).
20. Döhner, H., Stilgenbauer, S., James, M.R., Benner, A., Weilguni, T., Bentz, M., Fischer, K., Hunstein, W., and Lichter, P. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 89, 2516-2522 (1997).
21. Herling, M., Patel, K.A., Khalili, J., Schlette, E., Kobayashi, R., Medeiros, L.J., and Jones, D. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia 20, 280-285 (2006).
22. Soutschek, J., Akinc, A., Bramlage, B. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 (2004). First paper to demonstrate "knock down" of liver-expressed genes in vivo by modified siRNAs.
23. Scott, G.K., Mattie, M.D., Berger, C.E., Benz, S.C., and Benz, C.C. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res. 66, 1277-12781 (2006). First article to show that pharmacologic treatment with HDAC inhibitors alters miRNA expression.